Stem cell therapy and breast cancer treatment: Review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Sharp, Thomas E ^a   George, Jon C ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Cardiac regeneration; Chemotherapy cardiotoxicity; Differentiation; Paracrine factors; Stem cells

Indexed keywords

ADHESIN; BACTERIAL PROTEIN; EXOPOLYSACCHARIDE; FIBRONECTIN BINDING PROTEIN; FORMYLPEPTIDE RECEPTOR; NUCLEASE; PHENOL SOLUBLE MODULIN; PROTEINASE; STAPHYLOCOCCUS ALPHA TOXIN; TEICHOIC ACID; UNCLASSIFIED DRUG;

BACTERIAL GENE; BACTERIAL GROWTH; BIOFILM; BIOFILM DEVELOPMENT; BIOFILM DISSEMINATION; CATHETER INFECTION; EXTRACELLULAR MATRIX; GENE EXPRESSION; OPERON; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; REGULATOR GENE; REVIEW; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; UPREGULATION;

EID: 84915805266     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00299     Document Type: Review

References (155)

1. Society AC. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society (2013).
2. Ky B, Vejpongsa P, Yeh ETH, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 113(6):754-64. doi: 10.1161/CIRCRESAHA.113.300218
3. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol (2009) 53(24):2231-47. doi:10.1016/j.jacc.2009.02.050
4. Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J. Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology (2012) 122(4):253-9. doi:10.1159/000339858
5. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Buchar) (2013) 8(1):59-67.
6. Brower V. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. J Natl Cancer Inst (2013) 105(12):835-6. doi:10.1093/jnci/djt161
7. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 23(34):8597-605. doi:10.1200/JCO.2005.02.5841
8. Popat S, Smith IE. Therapy Insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol (2008) 5(6):324-35. doi:10.1038/ncponc1090
9. Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol (2007) 25(21):3031-7. doi:10.1200/JCO.2006.08.6595
10. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem (1986) 261(7):3060-7.
11. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 13(1):1-10. doi:10.1093/eurjhf/hfq213
12. Fiúza M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Therapy (2009) 26(1):9-17. doi:10.1007/s12325-009-0048-z
13. Fried G, Regev T, Moskovitz M. Trastuzumab-related cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat (2013) 142(1):1-7. doi:10.1007/s10549-013-2732-6
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 344(11):783-92. doi:10.1056/NEJM200103153441101
15. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 109(8):923-40. doi:10.1161/CIRCRESAHA.111.243147
16. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation (2002) 106(15):1913-8. doi:10.1161/01.CIR.0000034046.87607.1C
17. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 62(4):220-41. doi:10.3322/caac.21149
18. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis (2010) 53(2):105-13. doi:10.1016/j.pcad.2010.06.007
19. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2008) 26(32):5204-12. doi:10.1200/JCO.2007.15.6331
20. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med (1998) 339(13):900-5. doi:10.1056/NEJM199809243391307
21. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol (1996) 49(5):832-41.
22. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 29(6 Suppl 16):15-8. doi:10.1053/sonc.2002.37263
23. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res (2002) 62(23):6938-43.
24. Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys (2001) 49(4):1023-8. doi:10.1016/S0360-3016(00)01531-5
25. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol (2005) 23(19):4265-74. doi:10.1200/JCO.2005.04.173
26. Romond EH, Jeong J-H, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 30(31):3792-9. doi:10.1200/JCO.2011.40.0010
27. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 20(5):1215-21. doi:10.1200/JCO.20.5.1215
28. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res (1983) 43(2):460-72.
29. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T, et al. p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS One (2011) 6(3):e18005. doi:10.1371/journal.pone.0018005
30. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 56(2):185-229. doi:10.1124/pr.56.2.6
31. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation (2010) 121(2):276-92. doi:10.1161/CIRCULATIONAHA.109.895771
32. Ling LH, Oh JK, SchaffHV, Danielson GK, Mahoney DW, Seward JB, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation (1999) 100(13):1380-6. doi:10.1161/01.CIR.100.13.1380
33. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys (2007) 67(1):10-8. doi:10.1016/j.ijrobp.2006.08.071
34. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol (1998) 16(11):3502-8.
35. Santiago MJ, Hayes BD, Butler KH. Severe cardiotoxicity associated with ixabepilone use in metastatic breast cancer. Ann Pharmacother (2013) 47(4):e17. doi:10.1345/aph.1R681
36. Scherrer-Crosbie M. Markers of cardiotoxicity in breast cancer patients. Clin Adv Hematol Oncol (2013) 11(1):41-2.
37. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol (2005) 23(31):7811-9. doi:10.1200/JCO.2005.02.4091
38. Wieshammer S, Dreyhaupt J, Muller D, Momm F, Jakob A, Freund U. Cardiotoxicity and cancer therapy: treatment-related cardiac morbidity in patients presenting with symptoms suggestive of heart or lung disease. Oncology (2013) 85(3):137-44. doi:10.1159/000354299
39. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2010) 102(1):14-25. doi:10.1093/jnci/djp440
40. Hong RA, Iimura T, Sumida KN, Eager RM. Cardio-oncology/onco-cardiology. Clin Cardiol (2010) 33(12):733-7. doi:10.1002/clc.20823
41. Pituskin E, Haykowsky M, Mackey J, Thompson R, Ezekowitz J, Koshman S, et al. Rationale and design of the multidisciplinary approach to novel therapies in cardiology oncology research trial (MANTICORE 101-breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer (2011) 11:318. doi:10.1186/1471-2407-11-318
42. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature (2001) 410(6829):701-5. doi:10.1038/35070587
43. Mathieu M, Bartunek J, El Oumeiri B, Touihri K, Hadad I, Thoma P, et al. Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction. J Thorac Cardiovasc Surg (2009) 138(3):646-53. doi:10.1016/j.jtcvs.2008.12.031
44. Bel A, Messas E, Agbulut O, Richard P, Samuel JL, Bruneval P, et al. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation (2003) 108(Suppl 1):II247-52. doi:10.1161/01.cir.0000089040.11131.d4
45. Waksman R, Fournadjiev J, Baffour R, Pakala R, Hellinga D, Leborgne L, et al. Transepicardial autologous bone marrow-derived mononuclear cell therapy in a porcine model of chronically infarcted myocardium. Cardiovasc Radiat Med (2004) 5(3):125-31. doi:10.1016/j.carrev.2005.03.001
46. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature (2004) 428(6983):668-73. doi:10.1038/nature02460
47. Kajstura J, Rota M, Whang B, Cascapera S, Hosoda T, Bearzi C, et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res (2005) 96(1):127-37. doi:10.1161/01.RES.0000151843.79801.60
48. Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res (2010) 107(7):913-22. doi:10.1161/CIRCRESAHA.110.222703
49. Cai L, Johnstone BH, Cook TG, Tan J, Fishbein MC, Chen PS, et al. IFATS collection: human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem Cells (2009) 27(1):230-7. doi:10.1634/stemcells.2008-0273
50. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A (2009) 106(33):14022-7. doi:10.1073/pnas.0903201106
51. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J (2009) 30(22):2722-32. doi:10.1093/eurheartj/ehp265
52. Ren G, Roberts AI, Shi Y. Adhesion molecules: key players in mesenchymal stem cell-mediated immunosuppression. Cell Adh Migr (2011) 5(1):20-2. doi:10.4161/cam.5.1.13491
53. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell (2003) 114(6):763-76. doi:10.1016/S0092-8674(03)00687-1
54. Fischer KM, Cottage CT, Wu W, Din S, Gude NA, Avitabile D, et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation (2009) 120(21):2077-87. doi:10.1161/CIRCULATIONAHA.109.884403
55. Li Q, Guo Y, Ou Q, Chen N, Wu WJ, Yuan F, et al. Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. Basic Res Cardiol (2011) 106(5):849-64. doi:10.1007/s00395-011-0180-1
56. Vrtovec B, Poglajen G, Sever M, Lezaic L, Domanovic D, Cernelc P, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail (2011) 17(4):272-81. doi:10.1016/j.cardfail.2010.11.007
57. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res (2005) 96(2):151-63. doi:10.1161/01.RES.0000155333.69009.63
58. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest (2001) 107(11):1395-402. doi:10.1172/JCI12150
59. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis (2007) 49(6):421-9. doi:10.1016/j.pcad.2007.02.004
60. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, et al. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res (2013) 112(1):165-73. doi:10.1161/CIRCRESAHA.112.276519
61. Patel AN, Geffner L, Vina RF, Saslavsky J, Urschel HC Jr., Kormos R, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg (2005) 130(6):1631-8. doi:10.1016/j.jtcvs.2005.07.056
62. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA (2012) 308(22):2369-79. doi:10.1001/jama.2012.25321
63. Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res (2014) 114(8):1302-10. doi:10.1161/CIRCRESAHA.114.303180
64. Bolli R, Tang XL, Sanganalmath SK, Rimoldi O, Mosna F, Abdel-Latif A, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation (2013) 128(2):122-31. doi:10.1161/CIRCULATIONAHA.112.001075
65. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet (2012) 379(9819):895-904. doi:10.1016/S0140-6736(12)60195-0
66. Borchardt T, Braun T. Cardiovascular regeneration in non-mammalian model systems: what are the differences between newts and man? Thromb Haemost (2007) 98(2):311-8. doi:10.1160/th07-02-0153
67. Poss KD. Getting to the heart of regeneration in zebrafish. Semin Cell Dev Biol (2007) 18(1):36-45. doi:10.1016/j.semcdb.2006.11.009
68. Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev (2007) 87(2):521-44. doi:10.1152/physrev.00032.2006
69. Rubart M, Field LJ. Cardiac regeneration: repopulating the heart. Annu Rev Physiol (2006) 68:29-49. doi:10.1146/annurev.physiol.68.040104.124530
70. Oyama K, El-Nachef D, MacLellan WR. Regeneration potential of adult cardiac myocytes. Cell Res (2013) 23(8):978-9. doi:10.1038/cr.2013.78
71. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol (2010) 55(3):213-20. doi:10.1016/j.jacc.2009.03.095
72. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol (2012) 60(24):2504-12. doi:10.1016/j.jacc.2012.07.068
73. Groarke J, Tong D, Khambhati J, Cheng S, Moslehi J. Breast cancer therapies and cardiomyopathy. Med Clin North Am (2012) 96(5):1001-19. doi:10.1016/j.mcna.2012.07.008
74. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem (2006) 98(5):1076-84. doi:10.1002/jcb.20886
75. Cesselli D, Beltrami AP, Rigo S, Bergamin N, D'Aurizio F, Verardo R, et al. Multipotent progenitor cells are present in human peripheral blood. Circ Res (2009) 104(10):1225-34. doi:10.1161/CIRCRESAHA.109.195859
76. 7+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation (2004) 110(20):3213-20. doi:10.1161/01.CIR.0000147609.39780.02
77. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation (2003) 107(18):2294-302. doi:10.1161/01.CIR.0000070596.30552.8B
78. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva GV, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation (2004) 110(11 Suppl 1):II213-8. doi:10.1161/01.CIR.0000138398.77550.62
79. Galinanes M, Loubani M, Davies J, Chin D, Pasi J, Bell PR. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant (2004) 13(1):7-13. doi:10.3727/000000004772664842
80. Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation (2006) 114(1 Suppl):I101-7. doi:10.1161/CIRCULATIONAHA.105.000505
81. Fischer-Rasokat U, Assmus B, Seeger FH, Honold J, Leistner D, Fichtlscherer S, et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail (2009) 2(5):417-23. doi:10.1161/CIRCHEARTFAILURE.109.855023
82. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 97(7):3422-7. doi:10.1073/pnas.97.7.3422
83. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation (2003) 107(8):1164-9. doi:10.1161/01.CIR.0000058702.69484.A0
84. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood (1996) 87(1):1-13.
85. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol (1994) 12(1):28-36.
86. Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood (1997) 90(11):4313-20.
87. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8(4):315-7. doi:10.1080/14653240600855905
88. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol (2004) 36(4):568-84. doi:10.1016/j.biocel.2003.11.001
89. Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica (2010) 95(4):651-9. doi:10.3324/haematol.2009.015065
90. Hamamoto H, Gorman JH III, Ryan LP, Hinmon R, Martens TP, Schuster MD, et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann Thorac Surg (2009) 87(3):794-801. doi:10.1016/j.athoracsur.2008.11.057
91. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet (1970) 3(4):393-403.
92. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284(5411):143-7. doi:10.1126/science.284.5411.143
93. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation (1974) 17(4):331-40. doi:10.1097/00007890-197404000-00001
94. Caplan AI. Mesenchymal stem cells. J Orthop Res (1991) 9(5):641-50. doi:10.1002/jor.1100090504
95. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve (1995) 18(12):1417-26. doi:10.1002/mus.880181212
96. Li X, Yu X, Lin Q, Deng C, Shan Z, Yang M, et al. Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. J Mol Cell Cardiol (2007) 42(2):295-303. doi:10.1016/j.yjmcc.2006.07.002
97. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest (1999) 103(5):697-705. doi:10.1172/JCI5298
98. Reinecke H, Minami E, Zhu WZ, Laflamme MA. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res (2008) 103(10):1058-71. doi:10.1161/CIRCRESAHA.108.180588
99. Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med (2007) 4(Suppl 1):S21-6. doi:10.1038/ncpcardio0770
100. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res (2008) 103(11):1204-19. doi:10.1161/CIRCRESAHA.108.176826
101. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J (2006) 20(6):661-9. doi:10.1096/fj.05-5211com
102. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ, et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J (2007) 28(21):2667-77. doi:10.1093/eurheartj/ehm426
103. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation (2013) 127(2):213-23. doi:10.1161/CIRCULATIONAHA.112.131110
104. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2006) 24(2):386-98. doi:10.1634/stemcells.2005-0008
105. Ren G, Su J, Zhang L, Zhao X, Ling W, L'Huillie A, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells (2009) 27(8):1954-62. doi:10.1002/stem.118
106. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell (2008) 2(2):141-50. doi:10.1016/j.stem.2007.11.014
107. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood (2007) 110(10):3691-4. doi:10.1182/blood-2007-02-075481
108. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood (2007) 109(1):228-34. doi:10.1182/blood-2006-02-002246
109. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res (2013) 113(6):810-34. doi:10.1161/CIRCRESAHA.113.300219
110. Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 102(25):8966-71. doi:10.1073/pnas.0502678102
111. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A (2007) 104(35):14068-73. doi:10.1073/pnas.0706760104
112. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A (2005) 102(10):3766-71. doi:10.1073/pnas.0405957102
113. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet (2011) 378(9806):1847-57. doi:10.1016/S0140-6736(11)61590-0
114. Angert D, Berretta RM, Kubo H, Zhang H, Chen X, Wang W, et al. Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ Res (2011) 108(10):1226-37. doi:10.1161/CIRCRESAHA.110.239046
115. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res (2004) 95(9):911-21. doi:10.1161/01.RES.0000147315.71699.51
116. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A (2007) 104(45):17783-8. doi:10.1073/pnas.0706406104
117. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol (2010) 660:65-84. doi:10.1007/978-1-60761-705-1_5
118. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation (2005) 112(8):1128-35. doi:10.1161/CIRCULATIONAHA.104.500447
119. Williams AR, Suncion VY, McCall F, Guerra D, Mather J, Zambrano JP, et al. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc (2013) 2(3):e000140. doi:10.1161/JAHA.113.000140
120. Kubo H, Berretta RM, Jaleel N, Angert D, Houser SR. c-Kit+ bone marrow stem cells differentiate into functional cardiac myocytes. Clin Transl Sci (2009) 2(1):26-32. doi:10.1111/j.1752-8062.2008.00089.x
121. 34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation (2013) 128(11 Suppl 1):S42-9. doi:10.1161/CIRCULATIONAHA.112.000230
122. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell (2013) 154(4):827-42. doi:10.1016/j.cell.2013.07.039
123. Oskouei BN, Lamirault G, Joseph C, Treuer AV, Landa S, Da Silva J, et al. Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med (2012) 1(2):116-24. doi:10.5966/sctm.2011-0015
124. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation (1999) 100(19 Suppl):II247-56. doi:10.1161/01.CIR.100.suppl_2.II-247
125. Yoon YS, Wecker A, Heyd L, Park JS, Tkebuchava T, Kusano K, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest (2005) 115(2):326-38. doi:10.1172/JCI22326
126. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature (2004) 428(6983):664-8. doi:10.1038/nature02446
127. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature (2003) 425(6961):968-73. doi:10.1038/nature02069
128. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med (2004) 10(5):494-501. doi:10.1038/nm1040
129. Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, De Angelis A, et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res (2005) 97(7):663-73. doi:10.1161/01.RES.0000183733.53101.11
130. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev (2005) 85(4):1373-416. doi:10.1152/physrev.00013.2005
131. Leri A, Kajstura J, Anversa P. Mechanisms of myocardial regeneration. Trends Cardiovasc Med (2011) 21(2):52-8. doi:10.1016/j.tcm.2012.02.006
132. Duran JM, Makarewich CA, Trappanese DM, Gross P, Husain S, Dunn J, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res (2014) 114(11):1700-12. doi:10.1161/CIRCRESAHA.114.303200
133. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol (2012) 23(Suppl 7):vii155-66. doi:10.1093/annonc/mds293
134. Mirotsou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiseux N, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A (2007) 104(5):1643-8. doi:10.1073/pnas.0610024104
135. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2008) 111(3):1327-33. doi:10.1182/blood-2007-02-074997
136. Duran JM, Makarewich CA, Sharp TE, Starosta T, Zhu F, Hoffman NE, et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms. Circ Res (2013) 113(5):539-52. doi:10.1161/CIRCRESAHA.113.301202
137. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation (2004) 109(12):1543-9. doi:10.1161/01.CIR.0000124062.31102.57
138. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res (2004) 94(5):678-85. doi:10.1161/01.RES.0000118601.37875.AC
139. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial. J Am Coll Cardiol (2013) 63(2):110-22. doi:10.1016/j.jacc.2013.08.724
140. Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation (2010) 121(2):293-305. doi:10.1161/CIRCULATIONAHA.109.871905
141. Amado LC, Saliaris AP, Schuleri KH, St. John M, Xie J-S, Cattaneo S, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A (2005) 102(32):11474-9. doi:10.1073/pnas.0504388102
142. McCall FC, Telukuntla KS, Karantalis V, Suncion VY, Heldman AW, Mushtaq M, et al. Myocardial infarction and intramyocardial injection models in swine. Nat Protoc (2012) 7(8):1479-96. doi:10.1038/nprot.2012.075
143. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res (2011) 108(7):792-6. doi:10.1161/CIRCRESAHA.111.242610
144. Farahmand P, Lai TY, Weisel RD, Fazel S, Yau T, Menasche P, et al. Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation (2008) 118(14 Suppl):S130-7. doi:10.1161/CIRCULATIONAHA.107.757617
145. Fukushima S, Coppen SR, Lee J, Yamahara K, Felkin LE, Terracciano CM, et al. Choice of cell-delivery route for skeletal myoblast transplantation for treating post-infarction chronic heart failure in rat. PLoS One (2008) 3(8):e3071. doi:10.1371/journal.pone.0003071
146. Rota M, Padin-Iruegas ME, Misao Y, De Angelis A, Maestroni S, Ferreira-Martins J, et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res (2008) 103(1):107-16. doi:10.1161/CIRCRESAHA.108.178525
147. Shintani Y, Fukushima S, Varela-Carver A, Lee J, Coppen SR, Takahashi K, et al. Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure. J Mol Cell Cardiol (2009) 47(2):288-95. doi:10.1016/j.yjmcc.2009.05.009
148. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation (2005) 111(2):150-6. doi:10.1161/01.CIR.0000151812.86142.45
149. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol (1994) 12(1):37-44.
150. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells - biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther (2007) 9(1):204. doi:10.1186/ar2116
151. Zaragosi L-E, Ailhaud G, Dani C. Autocrine fibroblast growth factor 2 signaling is critical for self-renewal of human multipotent adipose-derived stem cells. Stem Cells (2006) 24(11):2412-9. doi:10.1634/stemcells.2006-0006
152. Coutu DL, Galipeau J. Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (2011) 3(10):920-33.
153. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Stromal derived factor-1 promotes the growth, survival and development of human bone marrow stromal stem cells. (2005) 105(10):3793-801. doi:10.1182/blood-2004-11-4349
154. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 54(24):2277-86. doi:10.1016/j.jacc.2009.06.055
155. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA (2014) 311(1):62-73. doi:10.1001/jama.2013.282909